Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Endometrial Neoplasms × durvalumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Ovarian Neoplasms 1 Non Small Cell Lung Cancer NSCLC 1 Lung Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Hepatocellular 1 Biliary Tract Neoplasms 1

Interventions

pembrolizumab 3 Paclitaxel 3 Carboplatin 2 sacituzumab govitecan 1 olaparib 1 lenvatinib 1 durvalumab 1 Taxes 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04269200 2025-12-23

DUO-E

AstraZeneca

Phase 3 Active not recruiting

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡